Tonix Pharmaceuticals (NASDAQ:TNXP) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research report report published on Saturday morning. The brokerage issued a hold rating on the stock.

Tonix Pharmaceuticals Stock Performance

NASDAQ:TNXP opened at $0.38 on Friday. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. Tonix Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $12.48. The stock has a market cap of $71.60 million, a P/E ratio of -0.01 and a beta of 2.02. The firm’s fifty day simple moving average is $0.28 and its 200 day simple moving average is $0.28.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million. As a group, research analysts predict that Tonix Pharmaceuticals will post -17.63 EPS for the current year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. PFG Investments LLC bought a new position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned approximately 0.12% of Tonix Pharmaceuticals at the end of the most recent quarter. Institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.